<DOC>
	<DOCNO>NCT02441283</DOCNO>
	<brief_summary>This rollover study assess resistance durability response ABT-493 and/or ABT-530 subject participate Phase 2 3 clinical study agent treatment chronic HCV .</brief_summary>
	<brief_title>A Study Assess Resistance Durability Response ABT-493 and/or ABT-530</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>1 . The subject male female 18 year age old 2 . The subject receive least one dose ABT493 and/or ABT 530 contain regimen prior AbbVie HCV Phase 2 3 study 3 . The interval last dose AbbVie DAA therapy previous clinical study enrollment Study M13576 must longer 2 year . 4 . The subject must voluntarily sign date inform consent form approve Independent Review Board Ethics Committee prior initiation studyspecific procedure . 5 . Subject complete posttreatment period eligible prior study . 1 . The investigator considers subject unsuitable study reason ( e.g. , failure comply study procedure prior AbbVie clinical study ) . 2 . Receipt investigational HCV antiviral treatment receive ABT493 and/or ABT530 prior study . 3 . Subjects experience nonvirologic treatment failure due premature discontinuation study drug prior study ABT493/ABT530 . 4 . Participation AbbVie 's Study M15942 protocol retreatment virologic failure prior Phase 2 3 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Sustained virologic response</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Chronic hepatitis C</keyword>
</DOC>